Apr 12, 2016
EUSA Pharma (EUSA) is a recently-established pharmaceutical company focusing on oncology and oncology supportive care. It has announced the acquisition of the global rights to a next generation formulation of EUSA’s current Caphosol® product from Arcoral Pharma. The product, Arcoral® Tab, is a topical oral agent used for the treatment of conditions resulting in reduced salivary flow such as hyposalivation and xerostomia caused by radiotherapy, surgery, mucositis, Sjögrens syndrome or obstruction of the salivary glands.
Arcoral® Tab is characterized by high concentrations of calcium and phosphate ions. It lubricates the mucosa of the tongue, mouth, and oropharynx, and assists in maintaining the integrity of the oral cavity using its mineralizing potential. Arcoral® Tab and Caphosol® have the same active ingredients, but come in the more convenient formulation of an effervescent tablet for producing the mouth rinse. EUSA Pharma wants to promote Arcoral® Tab directly through its specialist sales force in Europe, and through its international network of partners in a further 40 territories.
“We are delighted to acquire the global rights to Arcoral® Tab, which is an ideal strategic fit with our portfolio of specialty medicines, and our focus on oncology and oncology supportive care. This next generation formulation represents an important advance on our existing Caphosol® product, and demonstrates EUSA’s commitment to introducing next generation treatments to help specialists meet their patients’ needs. As a recently established company, we have great ambitions for EUSA, and we look forward to accelerating our growth through the acquisition and in-licensing of further products that fit our specialty focus,” said Lee Morley, EUSA Pharma’s Chief Executive Officer.